Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dependence01:17

Drug Dependence

1.0K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
1.0K
Time Course of Drug Effect01:14

Time Course of Drug Effect

2.1K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.1K
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

872
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
872
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

404
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
404
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.0K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.0K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

512
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
512

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II.

Leukemia·2026
Same author

Targeting CRTC2 reverses <i>STK11</i> mutant NSCLC tumor resistance to immunotherapy.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

A Legacy of Mentorship: A Tribute to Lewis Cantley.

Cancer discovery·2026
Same author

DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response.

Blood cancer discovery·2025
Same author

Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.

Cancer research communications·2025
Same author

VGLL2 and TEAD1 fusion proteins identified in human sarcoma drive YAP/TAZ-independent tumorigenesis by engaging EP300.

eLife·2025

Related Experiment Video

Updated: Jul 18, 2025

Genetic Barcoding with Fluorescent Proteins for Multiplexed Applications
13:14

Genetic Barcoding with Fluorescent Proteins for Multiplexed Applications

Published on: April 14, 2015

9.3K

Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.

Jennifer L Cotton1, Javier Estrada Diez1, Vivek Sagar1

  • 1Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

Cancer Research
|August 21, 2023
PubMed
Summary

Drug-tolerant cells in non-small cell lung cancer (NSCLC) exhibit distinct survival pathways and adapt gene expression to resist epidermal growth factor receptor inhibitors (EGFRi). Combination therapies targeting these resistant cells improve treatment efficacy.

More Related Videos

Competitive Genomic Screens of Barcoded Yeast Libraries
11:59

Competitive Genomic Screens of Barcoded Yeast Libraries

Published on: August 11, 2011

18.4K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.7K

Related Experiment Videos

Last Updated: Jul 18, 2025

Genetic Barcoding with Fluorescent Proteins for Multiplexed Applications
13:14

Genetic Barcoding with Fluorescent Proteins for Multiplexed Applications

Published on: April 14, 2015

9.3K
Competitive Genomic Screens of Barcoded Yeast Libraries
11:59

Competitive Genomic Screens of Barcoded Yeast Libraries

Published on: August 11, 2011

18.4K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Non-small cell lung cancer (NSCLC) with EGFR mutations often responds initially to EGFR inhibitors (EGFRi).
  • Residual disease persists, leading to treatment relapse due to drug-tolerant persister cells.
  • Understanding persister cell biology is crucial for improving EGFRi efficacy.

Purpose of the Study:

  • To track the origins and clonal evolution of drug-tolerant persister cells in EGFR-mutated NSCLC.
  • To decipher the molecular mechanisms underlying EGFR inhibitor (EGFRi) tolerance.
  • To identify strategies for overcoming treatment resistance.

Main Methods:

  • Utilized an expressed barcoding system for high-resolution tracking of clonal evolution.
  • Employed single-cell RNA sequencing for longitudinal profiling of gene expression.
  • Assessed drug sensitivity in response to EGFRi across numerous clones.

Main Results:

  • Drug-tolerant cells showed higher baseline expression of YAP and EMT survival pathways.
  • Persister cells differentially adapted gene expression upon EGFRi treatment compared to sensitive cells.
  • Combination therapies (MAPK targeting, chemotherapy) demonstrated greater efficacy than EGFRi alone.

Conclusions:

  • EGFRi-tolerant cells possess distinct biological features and adaptive capabilities.
  • Targeting heterogeneous tolerance mechanisms through combination therapy is effective.
  • This approach aids in developing improved diagnostics and treatments for drug-tolerant cells.